Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome
20
Jul
Blinatumomab Trimer Formation - Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous Dosing Regimen in Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Poster Abstract
Objectives
Blinatumomab is a bispecific T-cell engager (BiTE) that binds to CD3 on T-cells and CD19 on B-cells. It has been approved for use in Acute lymphoblastic leukemia (ALL) with a regimen that requires constant infusion for four weeks per treatment cycle [1-4].
Predicting on-target, off-tumor toxicity of Solitomab, an EpCAM/CD3 BiTE
Abstract
Applied BioMath Assess™ can be used to evaluate the risk of on-target, off-tumor toxicities for CD3 bispecific T-cell engagers and to make an early prediction about therapeutic index and projections of effective and tolerable doses for T-cell engagers in solid tumors. In this case study, we will demonstrate the ability to predict the on-target, off-tumor toxicity observed for solitomab. We will use this model to identify properties of tumor-associated antigens that could be more successfully targeted with a TCE.